GH/IGF axis
Conceptual educational illustration of GHRP-6 in a glass vial, labelled MOLECULE PROFILE.

View full illustrationSave GHRP-6

MOLECULE PROFILE

GHRP-6

Peptide or peptide-related

Ghrelin-receptor/GH-axis stimulation.

Sources checked · October 16, 2026

Published for review · Scientific, medical, translation and citation review pending. Reported uses are not authorized indications. Frequency reflects mentions in supplied sources, not sales or global clinical prevalence.

Identity and synonyms

Identity follows the supplied name and synonyms; no additional identity description is supplied.

Peptide or peptide-related · Peptide or peptide derivative

Detailed molecular class: GH-releasing peptide

Supplied sequence or chemical reference

See identity note; no supplier sequence accepted as verification.

Mechanism

Ghrelin-receptor/GH-axis stimulation.

Evidence and critical reading

Reported scientific and empirical uses

GH/IGF hormonal axis

Promoted for GH and appetite; acute pharmacology is not sustained functional gain.

Human evidence

No clinical outcome evidence for community recovery stacks established in this packet.

Preclinical evidence

Hormone release does not establish recovery or longevity benefit.

Critical reading and limitations

A pharmacokinetic study in nine volunteers does not prove muscle recovery or fat loss.

Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.

Source-specific regimens

Descriptive source observations, not individual recommendations.

Regulatory product labeling

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Human-study exposure

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Empirical handbook

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Regulation and safety

Jurisdiction-specific regulatory context

Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.

Adverse effects and unknowns

FDA flags potential cortisol effects and increased blood glucose associated with reduced insulin sensitivity.

FDA information includes glucose/insulin-sensitivity concerns; endocrine context matters.

Contraindications

See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.

A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.

Interactions

Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.

Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.

Studies and trials

Selected studies

PMID23099431 · Pharmacokinetics

Healthy men.

Single IV exposure.

Characterized PK, not hypertrophy, recovery or chronic safety.

Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.

n = 9

Trials attributed in the package

No trials are attributed in this record.

Trial registration does not establish efficacy or validate commercial material.

Query candidates; attribution pending

GHRP-6 · 0 unfiltered query results, not authenticated trials

Query verification: October 16, 2026

Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.

View trial registry query

Source issues and references

References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.

  1. PMID23099431

    Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers.

    Cabrales A, Gil J, Fernández E, Valenzuela C, Hernández F, García I, Hernández A, Besada V, Reyes O, Padrón G, Berlanga J, Guillén G, González LJ.

    October 16, 2026

  2. R06

    FDA: current bulk-substance safety-risk page

  3. SEARCH-PUBMED-ghrp-6

    PubMed/MED targeted search: TITLE_ABS:"GHRP-6" AND TITLE_ABS:healthy AND TITLE_ABS:volunteers

    October 16, 2026

  4. pdf01

    PEPNEXA 2.pdf

    October 16, 2026

  5. pdf02

    ELLA PEPTIDES.pdf

    October 16, 2026

  6. pdf03

    zlz list 26.8.5.pdf

    October 16, 2026

  7. pdf05

    PEPNEXA.pdf

    October 16, 2026

  8. pdf07

    US Peptide MangerCorp(1).pdf

    October 16, 2026

  9. pdf09

    PeptideFactory.pdf

    October 16, 2026

A community-based bilingual scientific education initiative for healthcare professionals and the general public across the Americas.Currently self-funded; no current sponsors. Formal governance and legal documentation pending.info@peptideamericas.org · Planned contact address — not active yet; please do not send messages.